1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sarepta’s Exondys Successor Bounces Back From Clinical Hold But All Eyes On Gene Therapy

 
• By Ayisha Sharma

The firm’s exon-skipping Duchenne muscular dystrophy asset will resume clinical study in the US following the lifting of a clinical hold but observers seem more invested in the fate of its gene therapy candidate for the condition.  

Grey telescope looking out over a body of water
Switzerland looks far afield to guarantee its patients have access to medtech products they need • Source: Shutterstock

Sarepta Therapeutics, Inc.’s Duchenne muscular dystrophy (DMD) candidate and potential Exondys successor, SRP-5051, has been released from a US clinical hold but investors appear keener on an anticipated gene therapy filing from the firm in this disease.

Sarepta revealed the US Food and Drug Administration had lifted the hold on the Phase II MOMENTUM trial of SRP-5051 (vesleteplirsen) following the provision of safety data the regulator had requested in June

More from Clinical Trials

More from R&D